Prognostic value of ERBB-1, VEGF, cyclin A, FOS, JUN and MYC in patients with squamous cell lung carcinomas
1998

Prognostic Factors in Squamous Cell Lung Carcinomas

Sample size: 121 publication Evidence: moderate

Author Information

Author(s): M Volm, W Rittgen, P Drings

Primary Institution: German Cancer Research Center

Hypothesis

Can combining the expression of molecular and cellular factors with clinical prognostic factors improve the diagnostic ability to predict prognosis in patients with squamous cell lung carcinomas?

Conclusion

The study found that the expression of certain molecular factors, such as VEGF and FOS, significantly correlates with shorter survival times in patients with squamous cell lung carcinomas.

Supporting Evidence

  • Patients with ERBB-1-positive tumors had a median survival of 92 weeks compared to over 260 weeks for negative tumors.
  • VEGF-positive tumors were associated with a median survival of 47 weeks versus 117 weeks for negative tumors.
  • FOS-positive tumors had a median survival of 92 weeks compared to over 260 weeks for negative tumors.

Takeaway

Doctors looked at how certain proteins in lung cancer cells can help predict how long patients might live. They found that some proteins are linked to shorter survival times.

Methodology

Immunohistochemistry was used to analyze the expression of various proteins in tumor samples from 121 patients with squamous cell lung carcinoma.

Limitations

The study did not include all patients' lymph node statuses and some data were missing for certain measurements.

Participant Demographics

The study included 121 patients, 113 men and 8 women, aged 37 to 75 years, with a mean age of 58 years.

Statistical Information

P-Value

0.006

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication